Item 5.07 Submission of Matters to a Vote of Security Holders.

Appointment of Stephen Willard as Chief Executive Officer and Director

On July 18, 2022, NRx Pharmaceuticals, Inc. (the "Company") held its annual meeting of stockholders (the "Annual Meeting"), at which quorum was present and voting throughout. During the course of the Annual Meeting, the Company's stockholders approved the two proposals listed below. The final results for the votes regarding each proposal are set forth in the following tables. Each of these proposals is described in detail in the Company's Proxy Statement.

Proposal 1. The Company's stockholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending on December 31, 2022. The results of the voting were as follows:





Votes For    Votes Against   Abstentions
19,713,375    11,367,376     13,135,962

Proposal 2. The Company's stockholders duly elected Chaim Hurvitz, by a plurality of votes cast, to serve as a Class I director until the 2025 Annual Meeting and until his successor is elected and qualified. The results of the voting were as follows:





Votes For    Votes Against   Abstentions   Broker Non-Votes
35,153,528         0           850,414        8,212,771






  2

© Edgar Online, source Glimpses